Celecoxib for the treatment of mild-to-moderate depression due to acute brucellosis: a double-blind, placebo-controlled, randomized trial

Journal of Clinical Pharmacy and Therapeutics

Volumn 40, Issue 4, 2015, Pages 441-446

  Jafari, S ^a   Ashrafizadeh, S G ^a   Zeinoddini, A ^b   Rasoulinejad, M ^a   Entezari, P ^b   Seddighi, S ^c   Akhondzadeh, S ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ILAM UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

brucellosis; celecoxib; clinical trial; depression; inflammation

Indexed keywords

BACTERIUM ANTIBODY; BRICELLA ANTIBODY; CELECOXIB; DOXYCYCLINE; PLACEBO; RIFAMPICIN; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; CYCLOOXYGENASE 2 INHIBITOR;

ABDOMINAL PAIN; ACUTE BRUCELLOSIS; ADULT; ANALYSIS OF COVARIANCE; ANTIBIOTIC THERAPY; ANTIBODY TITER; ARTICLE; BRUCELLOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DSM-IV-TR; FEMALE; HAMILTON DEPRESSION RATING SCALE; HEADACHE; HUMAN; INFECTION; MALE; MYALGIA; NAUSEA; OUTPATIENT; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTI-BACTERIAL AGENTS; ANTIDEPRESSIVE AGENTS; BRUCELLOSIS; CELECOXIB; CYCLOOXYGENASE 2 INHIBITORS; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84936985075     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12287     Document Type: Article

References (31)

1. Ariza J, Bosilkovski M, Cascio A, et al,. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med, 2007; 4: e317.
2. Eini P, Majzoobi MM, Ahmadpanah M, Mamani M,. Depressive disorder among brucellosis patients in Hamadan, Iran: a case-control study. Life Sci J, 2012; 9: 2534-2537.
3. Savas L, Onlen Y, Savas N, Yapar AF, Aydin M, Tugal O,. Prospective evaluation of 140 patients with brucellosis in the southern region of Turkey. Infect Dis Clin Pract, 2007; 15: 83-88.
4. Baldi PC, Giambartolomei GH,. Immunopathology of Brucella infection. Recent Pat Antiinfect Drug Discov, 2013; 8: 18-26.
5. Baldi PC, Giambartolomei GH,. Pathogenesis and pathobiology of zoonotic brucellosis in humans. Rev Sci Tech, 2013; 32: 117-125.
6. Demirdag K, Ozden M, Kalkan A, Godekmerdan A, Sirri Kilic S,. Serum cytokine levels in patients with acute brucellosis and their relation to the traditional inflammatory markers. FEMS Immunol Med Microbiol, 2003; 39: 149-153.
7. Akbulut H, Celik I, Akbulut A,. Cytokine levels in patients with brucellosis and their relations with the treatment. Indian J Med Microbiol, 2007; 25: 387.
8. Smith RS,. The macrophage theory of depression. Med Hypotheses, 1991; 35: 298-306.
9. Anisman H, Merali Z,. Cytokines, stress, and depressive illness. Brain Behav Immun, 2002; 16: 513-524.
10. Liu Y, Ho RC, Mak A,. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord, 2012; 139: 230-239.
11. proSchiepers OJ, Wichers MC, Maes M,. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry, 2005; 29: 201-217.
12. Konsman JP, Parnet P, Dantzer R,. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci, 2002; 25: 154-159.
13. Muller N,. The role of anti-inflammatory treatment in psychiatric disorders. Psychiatr Danub, 2013; 25: 292-298.
14. Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S,. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord, 2012; 141: 308-314.
15. Simon LS, Weaver AL, Graham DY, et al,. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA, 1999; 282: 1921-1928.
16. Muller N, Schwarz MJ, Dehning S, et al,. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry, 2006; 11: 680-684.
17. Akhondzadeh S, Jafari S, Raisi F, et al,. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety, 2009; 26: 607-611.
18. Hamilton M,. A rating scale for depression. J Neurol Neurosurg Psychiatry, 1960; 23: 56.
19. Khajavi D, Farokhnia M, Modabbernia A, Ashrafi M, Abbasi SH, Tabrizi M, Akhondzadeh S,. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry, 2012; 73: 1428-1433.
20. Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, et al,. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Psychiatry Res, 2014; 215: 540-546.
21. Shahmansouri N, Farokhnia M, Abbasi SH, et al,. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients. J Affect Disord, 2014; 155: 216-222.
22. Zeinoddini A, Ahadi M, Farokhnia M, Rezaei F, Tabrizi M, Akhondzadeh S,. L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial. J Psychiatr Res, 2014; 59: 125-131.
23. Chen CY, Tzeng NS, Chen YC,. Maintenance therapy of celecoxib for major depression with mimicking neuropsychological dysfunction. Gen Hosp Psychiatry, 2010; 32: 647. e647-647. e649.
24. Muller N, Schwarz MJ,. COX-2 inhibition in schizophrenia and major depression. Curr Pharm Des, 2008; 14: 1452-1465.
25. Guo JY, Li CY, Ruan YP, Sun M, Qi XL, Zhao BS, Luo F,. Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain. Eur J Pharmacol, 2009; 612: 54-60.
26. Johansson D, Falk A, Marcus MM, Svensson TH,. Celecoxib enhances the effect of reboxetine and fluoxetine on cortical noradrenaline and serotonin output in the rat. Prog Neuropsychopharmacol Biol Psychiatry, 2012; 39: 143-148.
27. Iyengar RL, Gandhi S, Aneja A, et al,. NSAIDs are associated with lower depression scores in patients with osteoarthritis. Am J Med, 2013; 126: 1017. e1011-1017. e1018.
28. Eren S, Bayam G, Ergönül Ö, et al,. Cognitive and emotional changes in neurobrucellosis. J Infect, 2006; 53: 184-189.
29. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B,. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res, 2007; 90: 179-185.
30. Mukherjee D, Nissen SE, Topol EJ,. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 2001; 286: 954-959.
31. Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R,. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. JRSM, 2016; 99: 132-140.